Sanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology Indications

Shots:

• Verastem to receive $5M up front, $42M as development & commercial milestones and royalties on sales of Copiktra in the licensed territories. Sanofi to get exclusive rights to develop and commercialize Copiktra and hold the marketing authorization & product license in Russia and CIS, Turkey, the Middle East & Africa
• The focus of the agreement is to expand Sanofi’s oncology portfolio in the emerging markets. Additionally, Sanofi has the right to collaborate with Verastem in global development & clinical activities of Copiktra
• Copiktra is an oral PI3K inhibitor (dual inhibitor of PI3K-delta and PI3K-gamma) and has received the US FDA’s approval for R/R CLL/SLL prior treated with 2L therapies with accelerated approval for FL prior treated with 2L therapies

Click here to­ read full press release/ article | Ref: Verastem | Image: Verastem